Premium
Lack of clonal BCRA2 gene deletion on chromosome 13in chronic lymphocytic leukaemia
Author(s) -
PANAYIOTIDIS PANOS,
GANESHAGURU K.,
ROWNTREE CLARE,
JABBAR SHIREEN A. B.,
HOFFBRAND VICTOR A.,
FORONI LETIZIA
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.1322949.x
Subject(s) - loss of heterozygosity , biology , exon , gene , chronic lymphocytic leukemia , chromosome , chromosome 13 , gene deletion , tumor suppressor gene , genetics , microbiology and biotechnology , cancer research , leukemia , allele , carcinogenesis , mutant
Chromosome 13q deletion is among the most common cytogenetic abnormalities in chronic lymphocytic leukaemia (CLL). We investigated the 13q14.3 deletion in 44 CLL patients by Southern blotting following purification of clonal B CLL cells to >90%. Two sets of probes were used to investigate the site of clonal deletion, the D13S25 and D13S319 markers (at 13q14.3) and probes for exons 11 and 26–27 of the BRCA2 gene (at 13q12). Homozygous and heterozygous deletion at the 13q14.3 region was found in five and 17 patients, respectively. Despite the recent report of the BRCA2 gene involvement in >80% of CLL patients, we failed to detect a single case of homozygous or heterozygous deletion involving the 13q12 region. Our data support previous findings that the 13q14.3, and not the 13q12 region, is the major site of candidate tumour suppressor gene(s) in CLL.